EUVIMEDEUVIMED entdecken
Crossref

Prevention of Anaphylaxis Episodes in Idiopathic Anaphylaxis by Omalizumab

Mitja Košnik, Lea Zugan, Matija Rijavec

International Archives of Allergy and Immunology · 2024

DOI: 10.1159/000538046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Mitja Košnik und 2 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia. Hauptthemen laut MEDLINE: Omalizumab, Anaphylaxis, Anti-Allergic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In 15–35 percent of patients with anaphylaxis, the triggering allergen cannot be found; therefore, a diagnosis of idiopathic anaphylaxis (IA) is made. We report on the outcomes in patients with IA treated with omalizumab.

Methods

We included consequent omalizumab-treated IA adult patients treated with omalizumab 300 mg every 4 weeks.

Results

Out of 7 patients, 6 were female, median age 40 years with the frequency of anaphylaxis episodes from 3 in 2 years to 5 in 4 months. Baseline tryptase ranged from 1.71 to 12.0 μg/L. An increase in tryptase during anaphylaxis was documented in 6 patients. Activating KIT p.D816V variant was detected in 2 patients. One patient also had hereditary alpha-tryptasemia (HαT). The duration of omalizumab treatment was 0.5–7.5 years. None of the patients have experienced an anaphylactic reaction since the start of treatment. Mild systemic reactions were reported in 6 patients (86%). The presence of underlying cMCD had no impact on the treatment outcome.

Conclusion

All patients in our study had complete responses to omalizumab. The presence of KIT p.D816V and HαT did not influence the response to omalizumab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabAnaphylaxisAnti-Allergic AgentsHumansFemaleAdultMaleMiddle AgedTreatment OutcomeTryptases

Stichwörter der Autor:innen

Clonal mast cell activation syndromeIdiopathic anaphylaxisOmalizumabTreatment

Substanzen

OmalizumabAnti-Allergic AgentsTryptases

Autor:innen und Institutionen

  • University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
  • Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Zitieren

APA

Košnik, M., Zugan, L., & Rijavec, M. (2024). Prevention of Anaphylaxis Episodes in Idiopathic Anaphylaxis by Omalizumab. International Archives of Allergy and Immunology. https://doi.org/10.1159/000538046

Vancouver

Košnik M, Zugan L, Rijavec M. Prevention of Anaphylaxis Episodes in Idiopathic Anaphylaxis by Omalizumab. International Archives of Allergy and Immunology. 2024. doi:10.1159/000538046

BibTeX
@article{Konik2024,
  author = {Košnik, Mitja and Zugan, Lea and Rijavec, Matija},
  title = {Prevention of Anaphylaxis Episodes in Idiopathic Anaphylaxis by Omalizumab},
  journal = {International Archives of Allergy and Immunology},
  year = {2024},
  doi = {10.1159/000538046}
}
Kostenlos starten →